Propeller Health recently completed a $14.5M Series B funding round, led by Safeguard Scientifics with participation from The Social+Capital Partnership. Propeller Health will use the funding to accelerate product development, strategic alliances, client services, sales and marketing as it tackles the $100 billion cost of treating asthma and chronic obstructive pulmonary disease (COPD).
Propeller is a digital therapeutic designed to help patients and their physicians better understand and control COPD, asthma and other respiratory disease, reducing preventable emergency room visits, hospitalizations and unnecessary suffering. The company has raised a total of $23M since its 2010 founding.
More information can be found on Xconomy here.